In April 2026, completed enrollment of the first subject in the Phase 2\/3 clinical trial for the expanded indication of pirfenidone targeting radiation-induced lung injury (RILI).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2160","jir_company_name":"GNI Group, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/2160-20260420-01.pdf","jir_short_summary":"In April 2026, completed enrollment of the first subject in the Phase 2\/3 clinical trial for the expanded indication of pirfenidone targeting radiation-induced lung injury (RILI).","jir_summary":"### Overview of the Clinical Trial\nGyre Pharmaceuticals, a consolidated subsidiary of GNI Group, Inc., completed the enrollment of the first subject in the Phase 2\/3 clinical trial of pirfenidone capsules (brand name: Iceury) targeting radiation-induced lung injury (RILI) in April 2026. This trial integratively and adaptively assesses safety and efficacy and obtained clinical trial commencement approval from the China National Medical Products Administration in March 2025.\n\n### Future Outlook and Impact on Investors\nRILI is a serious complication in thoracic tumor patients with limited treatment options. The expanded indication of pirfenidone addresses this unmet medical need. Gyre Pharmaceuticals will continue to advance clinical development aiming to improve patient quality of life. The impact of this clinical trial progress on the Group\u2019s consolidated financial results is considered minimal.","jir_financial_highlights":"Date of first subject enrollment completion: April 2026 (Unknown)\nDate of clinical trial commencement approval: March 2025 (Unknown)\nImpact of this clinical trial on consolidated financial results: Minimal (Unknown)","jir_category":"","jir_hashtags":"#GNIGroup, #NewDrugDevelopment, #ClinicalTrial","jir_key_figures":"First subject enrollment completion: April 2026\nClinical trial commencement approval obtained: March 2025 (China NMPA)\nFinancial impact of this clinical trial: Minimal","jir_meta_title":"[GNI Group] Completion of First Subject Enrollment in New Indication Clinical Trial of Pirfenidone | April 2026","jir_meta_description":"GNI Group completed enrollment of the first subject in a Phase 2\/3 clinical trial for the expanded indication of pirfenidone targeting radiation-induced lung injury (RILI) in April 2026.","jir_og_title":"[GNI Group] Completion of First Subject Enrollment in New Indication Clinical Trial of Pirfenidone","jir_og_description":"Progress in the clinical trial for expanded indication of pirfenidone for RILI. Completed enrollment of the first subject in April 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9370,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-41484","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n